Table 5.
Demographic data and FXIII levels of patients grouped according to stroke-related mortality by 14 days post-event.
| Variables | Survival (n = 114) | Death (n = 18) | P-value |
|---|---|---|---|
| Age, years | 68.0 (58.0–79.0) | 75.5 (63.0–83.3) | 0.130 |
| Male | 67 (58.8) | 11 (61.1) | 0.851 |
| Arterial hypertension | 87 (76.3) | 13 (73.7) | 0.707 |
| Atrial fibrillation | 28 (24.6) | 7 (38.9) | 0.201 |
| Hyperlipidaemia | 73 (64.0) | 9 (50.0) | 0.254 |
| Diabetes mellitus | 32 (28.1) | 8 (44.4) | 0.160 |
| Previous stroke | 39 (34.2) | 3 (16.7) | 0.138 |
| Active smoker | 28 (24.6) | 4 (22.2) | 0.830 |
| Serum glucose (mmol/L) | 6.4 (5.5–7.7) | 6.9 (5.6–8.4) | 0.490 |
| C-reactive protein (mg/L) | 3.0 (1.5–5.6) | 5.2 (2.2–9.6) | 0.112 |
| Antihypertensive therapy | 75 (65.8) | 12 (66.7) | 0.942 |
| Antiplatelet therapy | 48 (42.1) | 10 (55.5) | 0.285 |
| Time to treatment (min) with rtPA | 157.0 (125.0–180.0) | 144.0 (130.0–212.0) | 0.605 |
| Cardioembolic stroke | 23 (20.2) | 4 (22.2) | 0.841 |
| NIHSS on admission | 8.0 (5.0–13.0) | 14.0 (8.0–23.0) | 0.005 |
| ASPECT score on admission | 10.0 (9.0–10.0) | 9.5 (9.0–10.0) | 0.591 |
| FXIII activity (%) before thrombolysis | 129.0 ± 36.0 | 107.4 ± 31.5 | 0.017 |
| FXIII-A2B2 (mg/L) before thrombolysis | 22.9 ± 7.8 | 18.6 ± 4.8 | 0.026 |
| FXIII activity (%) immediately after thrombolysis | 127.1 ± 33.7 | 110.9 ± 32.0 | 0.061 |
| FXIII-A2B2 (mg/L) immediately after thrombolysis | 21.8 ± 6.8 | 18.5 ± 6.4 | 0.056 |
| FXIII activity (%) 24 h after thrombolysis | 119.9 ± 33.6 | 91.3 ± 36.5 | 0.004 |
| FXIII-A2B2 (mg/L) 24 h after thrombolysis | 20.2 ± 6.2 | 15.1 ± 6.5 | 0.005 |
Values are given as mean ± SD or median (IQR) or number (percentage). FXIII, factor XIII; rtPA, recombinant tissue type plasminogen activator; NIHSS, National Institute of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT score.